Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group

Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown. We evaluated children with osteosarcoma (OS) on two Children's Oncology Group trials with higher dose do...

Full description

Saved in:
Bibliographic Details
Published in:Cardio-oncology (London, England) England), 2019-10, Vol.5 (1), p.15-12, Article 15
Main Authors: Kopp, Lisa M, Womer, Richard B, Schwartz, Cindy L, Ebb, David H, Franco, Vivian I, Hall, David, Barkauskas, Donald A, Krailo, Mark D, Grier, Holcombe E, Meyers, Paul A, Wexler, Leonard H, Marina, Neyssa M, Janeway, Katherine A, Gorlick, Richard, Bernstein, Mark L, Lipshultz, Steven E
Format: Article
Language:English
Subjects:
Biomarkers
Bone cancer
Cancer therapies
Cardiomyocytes
Cardiomyopathy
Cardiotoxicity
Chemotherapy
Children & youth
Doxorubicin
Enrollments
Heart failure
Metastasis
Mortality
Oncology
Osteosarcoma
Patients
Pediatrics
Peptides
Sarcoma
Sexes
Studies
Teenagers
Tumors
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown. We evaluated children with osteosarcoma (OS) on two Children's Oncology Group trials with higher dose doxorubicin (375-600 mg/m ) preceded by dexrazoxane (10:1 dexrazoxane:doxorubicin dosing). They were evaluated after the minimum expected treatment time (METT), defined as 28 weeks. Cardiotoxicity was identified by echocardiography and serum N-terminal pro-brain natriuretic peptide (NT-proBNP). Second malignant neoplasm (SMN) data was collected. All children had normal left ventricular (LV) systolic function as measured by LV fractional shortening and no heart failure. The end-diastolic septal thickness scores (  
ISSN:2057-3804
2057-3804
DOI:10.1186/s40959-019-0050-9